NCT07813208Recruiting
Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
Real-world Investigation of Diagnosis, Treatment, and Survival Status of Children With Ph+ ALL in China
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 2 Sept 2026
- Start date
- 1 Aug 2025
- Primary completion date
- Sept 2026
- Lead sponsor
- The Children's Hospital of Zhejiang University School of Medicine
- NCT number
- NCT07813208
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Aug 2025 to the primary completion date, Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Irregular treatment not administered in accordance with the chemotherapy protocol.
- Previous or concurrent other malignancies.
Other illness
- Failure to receive standardized TKI therapy due to intolerance to TKIs, contraindications to TKI treatment, or other relevant factors.
Other
- Mixed-phenotype acute leukemia.
Who the study is looking for
- Age at diagnosis ranging from 1 month to 18 years.
- Positive for the BCR::ABL fusion gene.
- Serial quantitative MRD testing was routinely performed using multiparameter flow cytometry (MFC) and PCR (qRT-PCR or ddPCR) during treatment, with samples collected for both assays at identical time points.
- Standardized TKI therapy (imatinib, dasatinib, or other TKIs) was administered.
Age in the registry: 1 month to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Children's Hospital of Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.